Amphastar Pharmaceuticals/$AMPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Ticker
$AMPH
Sector
Primary listing
Employees
1,976
Headquarters
Website
AMPH Metrics
BasicAdvanced
$801m
10.89
$1.67
0.97
-
Price and volume
Market cap
$801m
Beta
0.97
52-week high
$31.26
52-week low
$16.65
Average daily volume
640k
Financial strength
Current ratio
3.853
Quick ratio
2.732
Long term debt to equity
87.278
Total debt to equity
88.749
Interest coverage (TTM)
5.56%
Profitability
EBITDA (TTM)
197.274
Gross margin (TTM)
47.34%
Net profit margin (TTM)
11.00%
Operating margin (TTM)
19.41%
Effective tax rate (TTM)
22.94%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
5.34%
Return on equity (TTM)
10.39%
Valuation
Price to earnings (TTM)
10.895
Price to revenue (TTM)
1.163
Price to book
1.05
Price to tangible book (TTM)
3.79
Price to free cash flow (TTM)
6.306
Free cash flow yield (TTM)
15.86%
Free cash flow per share (TTM)
2.88
Growth
Revenue change (TTM)
-1.39%
Earnings per share change (TTM)
-39.72%
3-year revenue growth (CAGR)
11.58%
10-year revenue growth (CAGR)
10.99%
3-year earnings per share growth (CAGR)
-1.98%
10-year earnings per share growth (CAGR)
96.40%
What the Analysts think about AMPH
Analyst ratings (Buy, Hold, Sell) for Amphastar Pharmaceuticals stock.
AMPH Financial Performance
Revenues and expenses
AMPH Earnings Performance
Company profitability
AMPH News
AllArticlesVideos
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
MarketBeat·1 week ago
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
Accesswire·2 weeks ago
Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference
Accesswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs